688139 海尔生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.8005.7338.5249.84315.720
总资产报酬率 ROA (%)1.3644.3316.4827.37311.566
投入资产回报率 ROIC (%)1.6525.2517.8478.89113.683

边际利润分析
销售毛利率 (%)47.55046.78947.98648.60248.154
营业利润率 (%)12.87211.43817.59419.22123.592
息税前利润/营业总收入 (%)13.35810.25815.53118.01722.872
净利润/营业总收入 (%)12.26710.95616.68318.06621.367

收益指标分析
经营活动净收益/利润总额(%)83.36782.08385.07872.25984.498
价值变动净收益/利润总额(%)3.66810.1287.28019.58410.027
营业外收支净额/利润总额(%)0.797-0.5980.032-0.900-0.051

偿债能力分析
流动比率 (X)2.5662.4492.5942.6932.945
速动比率 (X)2.2502.1312.2672.4302.717
资产负债率 (%)19.70120.17320.20519.64924.424
带息债务/全部投入资本 (%)6.0166.8985.0884.5668.219
股东权益/带息债务 (%)1,532.8501,324.5671,804.7702,021.3901,074.899
股东权益/负债合计 (%)386.089374.529373.850389.669299.903
利息保障倍数 (X)34.884-9.231-7.506-17.463-32.301

营运能力分析
应收账款周转天数 (天)62.79056.29340.31627.10816.850
存货周转天数 (天)89.80998.81388.30479.62074.708